Relatively little is known about the seminal genetic events that trigger the development of low-grade gliomas in children. Genetically engineered mouse models of the neurofibromatosis-1—inherited tumor predisposition syndrome have identified key intracellular growth control pathways, defined the contribution of the tumor microenvironment to glioma growth, and helped researchers understand the genetic basis for glioma susceptibility. In addition, genetically engineered mouse low-grade glioma models have recently been used in preclinical therapeutic studies to evaluate the efficacy of particular biologically based therapies and to define outcome measures.
CBTRUS 2005-2006 Primary Brain Tumors in the United States Statistical Report 1998-2002 Years Data Collected. Central Brain Tumor Registry of the United States. Available at: http://www.cbtrus.org. Accessed November 30, 2007.
2.
Louis DN, Ohgaki H, Wiester OD, et al, eds. WHO Classification of Tumours of the Central Nervous System. Vol 1. 4th ed. Geneva: WHO Press; 2007:312.
3.
Benesch M., Lackner H., Sovinz P., et al. Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. J Neurooncol.2006;78:199-205.
4.
Mulhern RK, Palmer SLNeurocognitive late effects in pediatric cancer. Curr Probl Cancer. 2003;27:177-197.
5.
Friedman JM, Gutmann DH, MacCollin M., et al. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis . Baltimore, MD: Johns Hopkins Press ; 1999.
6.
Listernick R. , Charrow J., Greenwald M., et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125:63-66.
7.
Guillamo JS, Creange A., Kalifa C., et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126:152-160.
8.
Gutmann DH, Donahoe J., Brown T., et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol. 2000;26:361-367.
9.
Rodriguez FJ , Perry A., Gutmann DH, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008;67:240-249.
10.
Schmandt SM , Packer RJ, Vezina LG, et al. Spontaneous regression of low-grade astrocytomas in childhood. Pediatr Neurosurg. 2000;32:132-136.
11.
Wimmer K., Eckart M., Meyer-Puttlitz B., et al. Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J Neuropathol Exp Neurol. 2002;61:896-902.
12.
Kluwe L., Hagel C., Tatagiba M., et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol. 2001;60:917-920.
13.
Bollag G., Clapp DW, Shih S., et al. Loss of NF1 results in activation of the RAS signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144-148.
14.
Guha A., Lau N., Huvar I., et al. RAS-GTP levels are elevated in human NF1 peripheral nerve tumors . Oncogene. 1996;12:507-513.
15.
Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of RAS proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-715.
16.
Sharma MK, Zehnbauer BA, Watson MA, et al. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology. 2005;65:1335-1336.
17.
Janzarik WG , Kratz CP, Loges NT, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics. 2007;38:61-63.
18.
Viskochil D. , Buchberg AM, Xu G., et al. Deletions and a trans-location interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell . 1990;62:187-192.
19.
Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181-186.
20.
Xu GF, O'Connell P., Viskochil D., etal. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell.1990;62:599-608.
21.
Bollag G., McCormick F.GTPase activating proteins. Semin Cancer Biol. 1992;3:199-208.
22.
Sebti SM, Hamilton ADFarnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Investig Drugs. 2000;9:2767-2782.
23.
Karp JE, Lancet JEDevelopment of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest. 2007;25:484-494.
24.
Widemann BC , Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006;24:507-516.
25.
Mahgoub N., Taylor BR, Gratiot M., et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 1999;94:2469-2476.
26.
Dasgupta B. , Li W., Perry A., et al. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005;65:236-245.
27.
Khalaf WF, Yang FC, Chen S., et al. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells. J Immunol. 2007;178:2527-2534.
28.
Morgan KJ, Rowley MA, Wiesner SM, et al. The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-RAS activation in Nf1-negative AML cells. Leuk Res. 2007;31:1107-1113.
29.
Dasgupta B. , Yi Y., Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005;65:2755-2760.
30.
Sandsmark DK , Pelletier C., Weber JD, et al. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol . 2007;22:895-903.
31.
Guertin DA, Sabatini DMDefining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.
32.
Pelletier CL , Maggi LB Jr, Brady SN, et al. TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res. 2007;67:1609-1617.
33.
Sandsmark DK , Zhang H., Hegedus B., et al. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res. 2007;67:4790-4799.
34.
Yu Y., Maggi LB Jr, Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 2006;26:3798-3809.
35.
Nellist M., Janssen B., Ward CJ, et al. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.
36.
van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997 ;277:805-808.
37.
Garami A., Zwartkruis FJ, Nobukuni T., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003 ;11:1457-1466.
38.
Inoki K., Li Y., Xu T., et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829-1834.
39.
Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259-1268.
40.
Franz DN, Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490-498.
41.
Haas-Kogan D., Shalev N., Wong M., et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998;8:1195-1198.
42.
Maehama T., Dixon JEThe tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378.
43.
Wang L., Harris TE, Roth RA, et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007;282:20036-20044.
44.
Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102:8573-8578.
45.
Tee AR, Anjum R., Blenis J.Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem. 2003;278:37288-37296.
46.
Collins VP, James CDGene and chromosomal alterations associated with the development of human gliomas. Faseb J. 1993;7:926-930.
47.
Calabrese C. , Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.
48.
Watters JJ, Schartner JM, Badie B.Microglia function in brain tumors. J Neurosci Res. 2005;81:447-455.
49.
Badie B., Schartner J.Role of microglia in glioma biology. Microsc Res Tech. 2001;54:106-113.
50.
Wesolowska A., Kwiatkowska A., Slomnicki L., et al. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene . 2008;27:918-930.
51.
Weissenberger J., Loeffler S., Kappeler A., et al. IL-6 is required for glioma development in a mouse model. Oncogene. 2004;23:3308-3316.
52.
Zhu Y., Ghosh P., Charnay P., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920-922.
53.
Bajenaru ML , Zhu Y., Hedrick NM, et al. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation . Mol Cell Biol. 2002;22:5100-5113.
54.
Bajenaru ML , Hernandez MR, Perry A., et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003;63:8573-8577.
Adamia S., Maxwell CA, Pilarski LMHyaluronan and hyaluronan synthases: potential therapeutic targets in cancer . Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:3-14.
58.
Yang L., Jackson E., Woerner BM, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007;67:651-658.
59.
Tong J., Hannan F., Zhu Y., et al. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci. 2002;5:95-96.
Warrington NM, Woerner BM, Daginakatte GC, et al. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007 ;67:8588-8595.
62.
Singh SK, Hawkins C., Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
63.
Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011-7021.
64.
Yuan X., Curtin J., Xiong Y., et al. Isolation of cancer stem cells from adult glioblastoma multiforme . Oncogene. 2004;23:9392-9400.
65.
Hemmati HD, Nakano I., Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100:15178-15183.
66.
Folkins C., Man S., Xu P., et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67:3560-3564.
67.
Reilly KM, Loisel DA, Bronson RT, et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 2000;26:109-113.
68.
Reilly KM, Tuskan RG, Christy E., et al. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A. 2004;101:13008-13013.
69.
McConville P., Hambardzumyan D., Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007 ;13:2897-2904.
70.
Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102:5524-5529.
71.
Dasgupta B. , Yi Y., Hegedus B., et al. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res. 2005;65:9843-9850.
72.
Gutmann DH, Hunter-Schaedle K., Shannon KMHarnessing preclinical mouse models to inform human clinical cancer trials . J Clin Invest. 2006;116:847-852.
73.
Hegedus B., Banerjee D., Yeh TH, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008;68:1520-1528.
74.
Banerjee D., Hegedus B., Gutmann DH, et al. Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. Neuroimage. 2007;35:1434-1437.
75.
Gorre ME, Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001 ;293:876-880.
76.
Shah NP, Nicoll JM, Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
77.
Giuriato S. , Felsher DWHow cancers escape their oncogene habit. Cell Cycle. 2003;2:329-332.
